4 129

Cited 40 times in

Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib

Authors
 Jae Hoon Lee  ;  Jun Yong Park  ;  Hye Jin Choi  ;  Jong Doo Lee  ;  Hyo Jung Seo  ;  Kwang-Hyub Han  ;  Sang Hoon Ahn  ;  Do Young Kim 
Citation
 Liver International, Vol.31(8) : 1144-1149, 2011 
Journal Title
 Liver International 
ISSN
 1478-3223 
Issue Date
2011
Abstract
BACKGROUND: Sorafenib (Nexavar) is an orally active multikinase inhibitor that is approved for the treatment of hepatocellular carcinoma (HCC). In this study, we used (18) F-2-fluoro-2-deoxyglucose ((18) F-FDG) with positron emission tomography (PET) to predict the treatment outcome of sorafenib in patients with advanced HCC. MATERIALS AND METHODS: A total of 29 patients with HCC were included. Baseline (18) F-FDG PET scans were performed a median of 14 days before sorafenib treatment. Sorafenib was administered orally at a dose of 400 mg twice daily. For statistical analysis, the standardized uptake value (SUV) of the most hypermetabolic lesion was obtained and assigned as the SUVmax for each patient. RESULTS: Among 29 patients, one patient achieved partial remission and 14 patients showed stable disease. The overall survival (OS) and progression free survival (PFS) were 5.1 months [95% confidence interval (CI): 0.0-12.0] and 3.8 months (95% CI: 1.4-6.2). The multivariate analysis of OS showed that four indices, Eastern Cooperative Oncology Group performance status, α-fetoprotein (AFP) concentration, portal vein thrombosis and SUVmax were significant prognostic factors (P=0.030, P=0.024, P=0.020 and P=0.015 respectively). AFP concentration and SUVmax were independent prognostic factors for PFS, too (P=0.003 and P=0.026 respectively). When the patients were divided into two groups: low SUVmax (n=10; <5.00) and high SUVmax (n=19;≥ 5.00), the low SUV group showed significantly longer OS and PFS (P=0.023 and P=0.042 respectively). CONCLUSION: Our study showed that the degree of FDG uptake is an independent prognostic factor in patients with HCC who undergo sorafenib treatment.
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/94874
DOI
10.1111/j.1478-3231.2011.02541.x
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Nuclear Medicine (핵의학교실)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
Yonsei Authors
김도영(Kim, Do Young) ; 박준용(Park, Jun Yong) ; 안상훈(Ahn, Sang Hoon) ; 이재훈(Lee, Jae Hoon) ; 이종두(Lee, Jong Doo) ; 최혜진(Choi, Hye Jin) ; 한광협(Han, Kwang Hyup)
사서에게 알리기
  feedback
Full Text
http://onlinelibrary.wiley.com/doi/10.1111/j.1478-3231.2011.02541.x/abstract
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse